Peer-influenced content. Sources you trust. No registration required. This is HCN.

ReachMDSuboptimal Response in Major Depressive Disorder: What’s Next When First-Line Treatment Fails? (CME)

Novel Therapeutics Treating the Adverse Events From SSRI and SNRI Monotherapy

In the ever-evolving field of psychiatry, the management of major depressive disorder (MDD) remains a complex challenge. The need for evidence-based strategies to address suboptimal treatment and adverse effects of SSRI and SNRI therapies is paramount. This CME program looks closely into the intricacies of screening tools, alternative treatment options, and innovative therapeutics, providing healthcare professionals with the knowledge and confidence to enhance patient care.

  • Target Audience: Interprofessional team including nurse practitioners, psychiatrists, physician assistants, physicians, nurses, and pharmacists specializing in psychiatry.
  • Learning Objectives: Translate screening tools, develop confidence in switching therapies, differentiate between alternative treatment options.
  • Accreditation: Jointly accredited by ACCME, ACPE, and ANCC; 0.50 IPCE credit available.
  • Content: Discussion on novel therapeutics for treating adverse events from SSRI and SNRI, including side effects, pretreatment evaluations, clinical pearls, and strategies for switching or augmenting therapies.

Related Posts

Did You Know?
Side effects are one of the primary reasons that people drop out of SSRI and SNRI treatment.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form